Wall Street brokerages expect that Kala Pharmaceuticals Inc (NASDAQ:KALA) will report earnings per share of ($0.58) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Kala Pharmaceuticals’ earnings. The highest EPS estimate is ($0.43) and the lowest is ($0.63). Kala Pharmaceuticals posted earnings per share of ($0.56) in the same quarter last year, which would indicate a negative year-over-year growth rate of 3.6%. The company is scheduled to report its next earnings report on Tuesday, November 6th.
On average, analysts expect that Kala Pharmaceuticals will report full year earnings of ($2.19) per share for the current year, with EPS estimates ranging from ($2.38) to ($1.72). For the next financial year, analysts anticipate that the business will report earnings of ($2.67) per share, with EPS estimates ranging from ($3.68) to ($1.21). Zacks’ EPS averages are an average based on a survey of sell-side research firms that cover Kala Pharmaceuticals.
Kala Pharmaceuticals (NASDAQ:KALA) last released its quarterly earnings data on Thursday, August 9th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.10).
Kala Pharmaceuticals stock opened at $10.38 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 9.79 and a quick ratio of 9.79. Kala Pharmaceuticals has a 12 month low of $10.34 and a 12 month high of $24.46.
Large investors have recently made changes to their positions in the stock. MetLife Investment Advisors LLC purchased a new stake in shares of Kala Pharmaceuticals during the 1st quarter valued at about $119,000. American International Group Inc. raised its holdings in shares of Kala Pharmaceuticals by 86.6% during the 1st quarter. American International Group Inc. now owns 9,119 shares of the company’s stock valued at $144,000 after buying an additional 4,232 shares during the period. Rhumbline Advisers purchased a new stake in shares of Kala Pharmaceuticals during the 2nd quarter valued at about $148,000. Paloma Partners Management Co purchased a new stake in shares of Kala Pharmaceuticals during the 2nd quarter valued at about $152,000. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Kala Pharmaceuticals by 489.8% during the 1st quarter. The Manufacturers Life Insurance Company now owns 11,778 shares of the company’s stock valued at $186,000 after buying an additional 9,781 shares during the period. Institutional investors and hedge funds own 72.19% of the company’s stock.
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Featured Article: Outstanding Shares, Buying and Selling Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.